What is the ROE (Return on Equity) of AstraZeneca this year?
The ROE of AstraZeneca this year is 0 undefined.
AstraZeneca ROE 2025
AstraZeneca ROE
0
Ticker
AZN.L
ISIN
GB0009895292
WKN
886455
In 2025, AstraZeneca's return on equity (ROE) was 0, a -100% increase from the 0.15 ROE in the previous year.
AstraZeneca Aktienanalyse
What does AstraZeneca do?
AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding AstraZeneca's Return on Equity (ROE)
AstraZeneca's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing AstraZeneca's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
AstraZeneca's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in AstraZeneca’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about AstraZeneca stock
How has the Return on Equity (ROE) of AstraZeneca developed compared to the previous year?
The ROE of AstraZeneca has increased by -100% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of AstraZeneca?
A high ROE indicates that AstraZeneca generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of AstraZeneca?
A low ROE can indicate that AstraZeneca is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of AstraZeneca affect the company?
A change in ROE (Return on Equity) of AstraZeneca can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of AstraZeneca?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of AstraZeneca?
Some factors that can influence AstraZeneca's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does AstraZeneca pay?
Over the past 12 months, AstraZeneca paid a dividend of 2.34 USD . This corresponds to a dividend yield of about 1.61 %. For the coming 12 months, AstraZeneca is expected to pay a dividend of 0.56 USD.
What is the dividend yield of AstraZeneca?
The current dividend yield of AstraZeneca is 1.61 %.
When does AstraZeneca pay dividends?
AstraZeneca pays a quarterly dividend. This is distributed in the months of September, March, September, March.
How secure is the dividend of AstraZeneca?
AstraZeneca paid dividends every year for the past 26 years.
What is the dividend of AstraZeneca?
For the upcoming 12 months, dividends amounting to 0.56 USD are expected. This corresponds to a dividend yield of 0.39 %.
In which sector is AstraZeneca located?
AstraZeneca is assigned to the 'Health' sector.
Wann musste ich die Aktien von AstraZeneca kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AstraZeneca from 3/24/2025 amounting to 2.09 USD, you needed to have the stock in your portfolio before the ex-date on 2/21/2025.
When did AstraZeneca pay the last dividend?
The last dividend was paid out on 3/24/2025.
What was the dividend of AstraZeneca in the year 2024?
In the year 2024, AstraZeneca distributed 2.346 USD as dividends.
In which currency does AstraZeneca pay out the dividend?
The dividends of AstraZeneca are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AstraZeneca stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von AstraZeneca
Our stock analysis for AstraZeneca Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AstraZeneca Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
